Indian Journal of Obstetrics and Gynecology Research · Nov 17, 2026

Role of anti-müllerian hormone (AMH) in assessing ovarian reserve: An umbrella meta-analysis review

By Katsaros N, Lazakis N, Gkogkos P et al.

Background : Anti-Müllerian hormone (AMH), produced by granulosa cells of pre-antral and small antral follicles, is widely acknowledged as a dependable biomarker for evaluating ovarian reserve. AMH has a high relationship with antral follicle count (AFC) and oocyte yield, but it doesn't do a good job of predicting natural conception. This meta-analysis sought to consolidate research from 2015 to 2025 about AMH's function in measuring ovarian reserve, examining geographic variations, risk factors, and predicted efficacy in assisted reproduction. Methods : In accordance with PRISMA 2020 standards, a search was conducted in MEDLINE, Embase, Web of Science, and the Cochrane Library from January 2015 to June 2025. Eligible studies evaluated AMH in relation to AFC, oocyte yield, suboptimal or elevated ovarian response, pregnancy, live birth, or the time of menopause. Data extraction encompassed demographic characteristics, assay type, and effect measurements (correlation coefficients, AUCs, odds ratios). We utilized QUADAS-2 and ROBINS-I to check for bias. We used random-effects meta-analysis to combine the estimates. Outcomes: Thirty-eight studies (n = 24,560) fulfilled the inclusion criteria, with 32 yielding extractable data for meta-analysis. The pooled correlation between AMH and AFC was 0.69 (95% CI: 0.64–0.73), while the association between AMH and oocyte yield was 0.58 (95% CI: 0.53–0.62). AMH predicted a poor ovarian response with an AUC of 0.83 and a good response with an AUC of 0.84. The prediction of live birth was moderate (AUC = 0.62). Low AMH prevalence (<1 ng/mL) varied geographically, from 15% in Europe to 25% in Africa. Smoking, being overweight, having surgery on the ovaries, and chemotherapy were all linked to low AMH. On the other hand, PCOS was linked to high AMH. Age was the most important factor, and the decline sped up after 35 years. Conclusions : AMH is a strong biomarker for checking ovarian reserve and customizing stimulation regimes in IVF. Its interpretation ought to be age- and assay-specific, amalgamated with AFC and clinical history. When giving clinical advice, it's important to think about geographic differences and risk factors that can be changed. Standardizing AMH tests and combining them with new predictive tools could make them more useful in the clinic. Anti-Müllerian hormone, Ovarian reserve, Antral follicle count, IVF, Biomarkers, Menopause prediction.

doi.org/10.18231/j.ijogr.14218.1787831364Open accessBiomarkers

AgingResearch.News